Carrick Targets Ovarian Cancer With BTG Deal, Entices Celgene’s Former Top Deal Maker
In a busy week, Carrick Therapeutics has added to its oncology pipeline, as well as bringing in Celgene deal maker George Golumbeski.
You may also be interested in...
Private Company Edition: Perceptive/Xontogeny, Abingworth, Kizoo and Droia closed venture capital funds. New biopharma VC financings also include a $105m series C round for Elpiscience and $92m for newly launched Interline.
Private Company Edition: BIO comments suggest definitions of personal data expand the scope of foreign investments in biotech companies that must be reviewed by the Committee on Foreign Investment in the United States (CFIUS). Also, NeuroRx’s $95m deal leads recent private financings.
Boston Scientific CEO says US group has been tracking UK-based BTG "for more than two years" and that interventional medicine is a key attraction.